おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
dextranomer
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Dextranomer EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
最新バージョンのいずれかを選択してください：
I Alova et al.
Journal of pediatric urology, 8(1), 40-46 (2011-02-01)
To evaluate outcome of further continence procedures after failure of endoscopic injections of dextranomer-based bulking agent. From 1997, 89 children (3-18 years) and one young adult were treated for incontinence with 145 endoscopic injections of dextranomer. On evaluation, each patient
David Ben-Meir et al.
The Journal of urology, 188(1), 258-261 (2012-05-19)
We histologically investigated the cause of failed endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid injections in children. A total of 192 children underwent dextranomer/hyaluronic acid injection at our institution between January 2008 and September 2010. The study population consisted
Fiona Smith et al.
The Cochrane database of systematic reviews, (5)(5), CD006214-CD006214 (2011-05-13)
Surgical wounds that become infected are often debrided because clinicians believe that removal of this necrotic or infected tissue will expedite wound healing. There are numerous methods available but no consensus on which one is most effective for surgical wounds.
Intermediate to long-term follow-up indicates low risk of recurrence after double HIT endoscopic treatment for primary vesico-ureteral reflux.
Ilker Akyol
Journal of pediatric urology, 8(4), 449-449 (2011-11-08)
Johan Danielson et al.
Diseases of the colon and rectum, 52(6), 1101-1106 (2009-07-08)
NASHA Dx gel has been used extensively for treatments in the field of urology. This study was performed to evaluate NASHA Dx gel as an injectable anal canal implant for the treatment of fecal incontinence. Thirty-four patients (5 males, 29
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
